APYX - Apyx Medical Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
4.5000
+0.0100 (+0.22%)
As of 9:46AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close4.4900
Open4.4500
Bid4.4500 x 900
Ask4.5000 x 800
Day's Range4.3700 - 4.5000
52 Week Range2.8050 - 8.5900
Volume5,939
Avg. Volume131,079
Market Cap153.829M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.4700
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.75
  • WeissLaw LLP: Apyx Medical Corporation is the Subject of a Legal Investigation
    PR Newswire

    WeissLaw LLP: Apyx Medical Corporation is the Subject of a Legal Investigation

    WeissLaw LLP, a national class action and shareholders' rights law firm with offices in New York, California and Georgia, announces an investigation of Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical Corp.," or the "Company").

  • Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?
    PR Newswire

    Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?

    Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of the companies listed below.

  • NanoString Technologies (NSTG) Surges: Stock Moves 10.3% Higher
    Zacks

    NanoString Technologies (NSTG) Surges: Stock Moves 10.3% Higher

    NanoString Technologies (NSTG) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

  • Here is What Hedge Funds Think About Apyx Medical Corporation (APYX)
    Insider Monkey

    Here is What Hedge Funds Think About Apyx Medical Corporation (APYX)

    Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

  • Business Wire

    Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020

    Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the second quarter of fiscal year 2020 will be released before the market opens on Monday, August 10.

  • Benzinga

    P/E Ratio Insights for Apyx Medical

    Looking into the current session, Apyx Medical Inc. (NASDAQ: APYX) shares are trading at $5.60, after a 17.22% spike. Moreover, over the past month, the stock increased by 19.72%, but in the past year, fell by 2.39%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session.The stock is currently above from its 52 week low by 99.75%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with Medical Devices stocks, and capitalize on the lower share price observed over the year.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Apyx Medical Inc. has a lower P/E than the aggregate P/E of 6.44 of the Medical Devices industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 17 Healthcare Stocks Moving In Tuesday's Pre-Market Session * Apyx Medical: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Apyx Spikes 45% In Pre-Market On Nod To Sell Helium Products In New Countries
    SmarterAnalyst

    Apyx Spikes 45% In Pre-Market On Nod To Sell Helium Products In New Countries

    Shares in Apyx Medical Corp. (APYX) spiked 45% in pre-market trading after the medical devices manufacturer won regulatory approval to sell its Helium Plasma technology products in five new countries.The stock leaped to $6.93. Apyx received approval to sell its Helium Plasma technology products in Australia, Brazil, Israel, Taiwan and Thailand. The company said it has contracted with distributors to market its products in each country. The products are sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market.Renuvion, which is used for cosmetic medical procedures such as dermal resurfacing, is a device using the helium technology to apply energy beneath the skin, causing a contraction effect that’s gentle on tissue. J-Plasma is a device used in cosmetic surgery for cutting, coagulation, and ablation of tissue.“We have been focused on pursuing regulatory clearances in international markets as one of our key strategic priorities to enhance Apyx Medical’s long-term growth profile,” said Apyx CEO and President Charlie Goodwin. “This strategy is based on the prudent expansion of our commercial footprint outside the U.S. by securing the requisite product registrations for our Helium Plasma Technology products, and identifying strong distribution partners in each respective market.”Goodwin added that he sees great growth opportunity in Brazil, which is estimated to be the second largest cosmetic surgery market in the world in terms of both the total number of procedures performed and the number of surgeons.“We shipped an initial commercial order to our distributor in Brazil in late-June and we expect to ship our initial commercial orders to each of the other new countries over the second half of 2020,” Goodwin said.Shares in Apyx have been hit hard this year, plunging some 43%. The stock rose 2.1% to $4.78 as of Monday’s close.Five-star analyst Matthew O'Brien at Piper Sandler maintained a Buy rating on the stock with a $7 price target, saying that the regulatory approval is an "important step" for building out the company's international customer base and should generate a "nice chunk" of growth in the coming years.O'Brien added that although Apyx’s shares are still down significantly year-to-date, he believes the company remains in sound financial shape and he expects the stock to recover as the coronavirus pandemic begins to subside.Related News: Merck’s Gardasil Receives FDA Nod For Expanded Cancer Indications Evoke Pharma Pops 86% On FDA Approval Of Gimoti Nasal Spray Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug More recent articles from Smarter Analyst: * The Rise of E-Commerce and Cloud Services Positions Amazon (AMZN) for the Win * Facebook Faces More Ad Boycotts, But This Analyst Expects Minimal Impact * 3 "Strong Buy" Penny Stocks With Explosive Upside Ahead * Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst

  • Apyx Medical Corporation Announces Regulatory Clearance to Market and Sell its Helium Plasma Technology Products in Five New Countries
    Business Wire

    Apyx Medical Corporation Announces Regulatory Clearance to Market and Sell its Helium Plasma Technology Products in Five New Countries

    Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that the Company has obtained regulatory approval to market and sell its Helium Plasma Technology products in five new countries: Australia, Brazil, Israel, Taiwan and Thailand. The Company has contracted with distributors to market and sell its products in each country.

  • NOTICE For Investors In NASDAQ: APYX Shares: Update in Lawsuit against Apyx Medical Corporation announced by Shareholders Foundation
    Newsfile

    NOTICE For Investors In NASDAQ: APYX Shares: Update in Lawsuit against Apyx Medical Corporation announced by Shareholders Foundation

    San Diego, California--(Newsfile Corp. - June 16, 2020) - The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Apyx Medical Corporation (NASDAQ: APYX) shares.Investors, who purchased shares of Apyx Medical Corporation (NASDAQ: APYX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.On April 17, 2019, a lawsuit was filed against Apyx Medical Corporation /k/a/ Bovie Medical Corporation over alleged Securities ...

  • Kaskela Law LLC Announces Investigation of Apyx Medical Corp. (APYX) and Encourages Long-Term APYX Stockholders to Contact the Firm
    PR Newswire

    Kaskela Law LLC Announces Investigation of Apyx Medical Corp. (APYX) and Encourages Long-Term APYX Stockholders to Contact the Firm

    Kaskela Law LLC announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") on behalf of the Company's stockholders.

  • GlobeNewswire

    Lifshitz Law Firm, P.C. Announces Investigation of Apyx Medical Corporation (APYX), Honeywell International Inc. (HON), Immunomedics, Inc. (IMMU), and Zuora, Inc. (ZUO)

    NEW YORK, June 05, 2020 -- Apyx Medical Corporation (APYX) Lifshitz Law Firm, P.C. announces investigation into possible breaches of fiduciary duty by certain of Apyx’s.

  • ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Apyx Medical Corporation - APYX
    PR Newswire

    ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Apyx Medical Corporation - APYX

    Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX) resulting from allegations that Apyx may have issued materially misleading business information to the investing public.

  • Why Apyx (APYX) Stock Might be a Great Pick
    Zacks

    Why Apyx (APYX) Stock Might be a Great Pick

    Apyx (APYX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Kaskela Law LLC Announces Stockholder Investigation of Apyx Medical Corp. (APYX) and Encourages Long-Term APYX Stockholders to Contact the Firm
    Business Wire

    Kaskela Law LLC Announces Stockholder Investigation of Apyx Medical Corp. (APYX) and Encourages Long-Term APYX Stockholders to Contact the Firm

    Kaskela Law LLC is investigating Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") on behalf of the Company’s stockholders.

  • Will Apyx Medical Continue to Surge Higher?
    Zacks

    Will Apyx Medical Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor of Apyx Medical

  • SHAREHOLDER ALERT: Apyx Medical Corporation Officers and Directors Under Investigation by Schubert Law Firm for Allegedly Misleading Statements Concerning Its December 2018 FDA Application for Expanded Uses of J-Plasma Technology
    PR Newswire

    SHAREHOLDER ALERT: Apyx Medical Corporation Officers and Directors Under Investigation by Schubert Law Firm for Allegedly Misleading Statements Concerning Its December 2018 FDA Application for Expanded Uses of J-Plasma Technology

    Schubert Jonckheer & Kolbe LLP is investigating potential shareholder derivative claims on behalf of stockholders of Apyx Medical Corporation (NASDAQ: APYX) related to the company's statements regarding its December 2018 application to the U.S. Food and Drug Administration for expanded uses of Apyx's J-Plasma technology—the company's key growth product.

  • GlobeNewswire

    Lifshitz Law Firm, P.C. Announces Investigation of Advance Auto Parts, Inc., (AAP), Apyx Medical Corporation (APYX), Dycom Industries, Inc. (DY) and Wright Medical Group N.V. (NASDAQ: WMGI)

    NEW YORK, May 15, 2020 -- Advance Auto Parts, Inc. (AAP) Lifshitz Law Firm announces investigation into possible breaches of fiduciary duty by certain of Advance Auto Parts’.

  • Apyx Medical Corp (APYX) Q1 2020 Earnings Call Transcript
    Motley Fool

    Apyx Medical Corp (APYX) Q1 2020 Earnings Call Transcript

    Image source: The Motley Fool. Apyx Medical Corp (NASDAQ: APYX)Q1 2020 Earnings CallMay 11, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, ladies and gentlemen, and welcome to the first quarter fiscal-year 2020 earnings call for Apyx Medical Corporation [Operator instructions].

  • Apyx Medical (APYX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Apyx Medical (APYX) Reports Q1 Loss, Misses Revenue Estimates

    Apyx (APYX) delivered earnings and revenue surprises of 72.73% and -5.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Apyx Medical: Q1 Earnings Insights

    Shares of Apyx Medical (NASDAQ:APYX) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share fell 42.86% over the past year to ($0.20), which beat the estimate of ($0.25).Revenue of $4,997,000 less by 14.19% year over year, which missed the estimate of $5,200,000.Outlook Apyx Medical hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 11, 2020View more earnings on APYXTime: 08:01 PM ETWebcast URL: https://78449.themediaframe.com/dataconf/productusers/apyx/mediaframe/36949/indexl.htmlRecent Stock Performance Company's 52-week high was at $8.5952-week low: $2.81Price action over last quarter: down 24.31%Company Profile Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. The company's product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives majority revenue.See more from Benzinga * Recap: Contura Energy Q1 Earnings * Recap: Vuzix Q1 Earnings * Recap: WAVE Life Sciences Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Apyx Medical Corporation Reports First Quarter 2020 Financial Results
    Business Wire

    Apyx Medical Corporation Reports First Quarter 2020 Financial Results

    Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its first quarter ended March 31, 2020.

  • GlobeNewswire

    Update in Lawsuit against Apyx Medical Corporation (NASDAQ: APYX) announced by Shareholders Foundation

    On April 17, 2019, a lawsuit was filed against Apyx Medical Corporation /k/a/ Bovie Medical Corporation over alleged Securities Laws Violations. The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint, that, as a result, the clinical study did not support the Company’s application for regulatory clearance, that, as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis. On September 3, 2019, an amended complaint was filed, and on October 3, 2019, the defendants filed their motion to dismiss the case.

  • SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Apyx Medical Corporation and Encourages Investors with Losses to Contact the Firm
    ACCESSWIRE

    SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Apyx Medical Corporation and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 20, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ:APYX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Apyx admitted on March 16, 2020, that its financial results for multiple periods, including the 12 months ending December 31, 2019, the quarterly statements for the three and nine-months periods ending September 30, 2018, and the three months ending March 31, 2019, could no longer be considered reliable and would require restating.